Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 3/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.46 |
| ▸ | CD38 | P28907 | 1/20 | 0.45 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3508894 | 0.94 | HSD11B1 (0.61) | HSD11B1ALDH1A1HPGDGRM5CNR2 | |
| SCHEMBL3508899 | 0.94 | HSD11B1 (0.61) | HSD11B1ALDH1A1HPGDGRM5CNR2 | |
| SCHEMBL24150310 | 0.94 | HSD11B1 (0.60) | HSD11B1ALDH1A1HPGDGRM5CNR2 | |
| SCHEMBL6083571 | 0.93 | CD38 (0.49) | HSD11B1ALDH1A1HPGDGRM5CNR2 | |
| SCHEMBL6083575 | 0.93 | CD38 (0.49) | HSD11B1ALDH1A1HPGDGRM5CNR2 | |
| SCHEMBL2593387 | 0.92 | HSD11B1 (0.63) | HSD11B1ALDH1A1CNR2CNR1PARP1 | |
| SCHEMBL24149920 | 0.90 | CNR2 (0.59) | HSD11B1ALDH1A1HPGDGRM5CNR2 | |
| SCHEMBL24150891 | 0.90 | SMYD3 (0.49) | HSD11B1ALDH1A1HPGDGRM5CNR2 | |
| SCHEMBL30039553 | 0.89 | CD38 (0.60) | HSD11B1ALDH1A1HPGDGRM5CNR2 | |
| SCHEMBL24148772 | 0.87 | HSD11B1 (0.51) | HSD11B1ALDH1A1HPGDGRM5PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066393-B2 | Indolin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066393-B2 | Indolin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-07-20 | — | — | US | disclosed |
| CN-108349944-B | Indolin-2-one derivatives | 豪夫迈·罗氏有限公司 | 2021-03-30 | — | — | CN | disclosed |
| US-20200299278-A1 | INDOLIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200299278-A1 | INDOLIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10710985-B2 | Indolin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10710985-B2 | Indolin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-3371168-B1 | INDOLIN-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-05-27 | — | — | EP | disclosed |
| EP-3371168-B1 | INDOLIN-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-05-27 | — | — | EP | disclosed |
| EP-3371168-A1 | INDOLIN-2-ONE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-09-12 | — | — | EP | disclosed |
| EP-2483251-B1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| US-8664220-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664220-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664220-B2 | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130072490-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072490-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072490-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC. (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2483251-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | Amira Pharmaceuticals, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011041462-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011041462-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072490-A1 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | HSD11B1 2258/4885ALDH1A1 3990/4885HPGD 2086/4885 |
| US-10710985-B2 | Indolin-2-one derivatives | GRIN2B, GRIN2A, TPH2 | HSD11B1 410/4885ALDH1A1 599/4885HPGD 2366/4885 |
| US-11066393-B2 | Indolin-2-one derivatives | GRIN2B, GRIN2A, TPH2 | HSD11B1 410/4885ALDH1A1 599/4885HPGD 2366/4885 |
| US-20200299278-A1 | INDOLIN-2-ONE DERIVATIVES | GRIN2B, GRIN2A, TPH2 | HSD11B1 410/4885ALDH1A1 599/4885HPGD 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.